by telrheum | May 19, 2024 | Biologic Therapy, Infections, Lupus, Rheumatoid Arthritis, Rituximab, Vasculitis
The article “Risk of Severe Infections Associated with Immunoglobulin Deficiency Under Rituximab Therapy in Immune Mediated Inflammatory Diseases” by Claire Rempenault and colleagues evaluates the connection between severe infections and immunoglobulin deficiency in...
by telrheum | Apr 6, 2024 | Vasculitis, Biologic Therapy, Remove term: eosinophilic granulomatosis with polyangiitis eosinophilic granulomatosis with polyangiitis
The MANDARA study explored how effective and safe benralizumab is compared to mepolizumab for treating Eosinophilic Granulomatosis with Polyangiitis (EGPA), a condition that typically requires long-term treatment with oral glucocorticoids and immunosuppressants. This...
by telrheum | Mar 24, 2024 | Biologic Therapy, Rheumatic Drugs, Vasculitis
The MAINTANCAVAS study, short for “Maintenance of ANCA Vasculitis Remission by Intermittent Rituximab Dosing,” was a clinical trial aimed at determining the best strategy to maintain remission in patients with ANCA vasculitis who have previously been...
by telrheum | Mar 8, 2024 | Biologic Therapy, Vasculitis
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare disease that causes inflammation in small blood vessels and involves a type of white blood cell called eosinophils. Benralizumab, a type of targeted therapy designed to block a specific part of the immune...
